April 1, 1992The Medical Journal of Australia
Treatment of ventricular arrhythmias after CAST
Why the study?
Do antiarrhythmic agents (flecainide, encainide, or moricizine) reduce mortality in patients with prior myocardial infarction and asymptomatic ventricular premature beats?
Population
Patients with a myocardial infarction which occurred six days to two years previously and with asymptomatic…
Comparison
Antiarrhythmic agents vs Placebo
Design
Review
Follow-up
mean 10 months (in the discussed CAST trial)
Authors
Discussion
Loading...
Member takes
Implication
Avoid these agents post-MI; leaves open safer strategies for ventricular ectopy management.
Structured PICO
Do antiarrhythmic agents (flecainide, encainide, or moricizine) reduce mortality in patients with prior myocardial infarction and asymptomatic ventricular premature beats?
P
Population
Patients with a myocardial infarction which occurred six days to two years previously and with asymptomatic ventricular premature beats
I
Intervention
Antiarrhythmic agents (flecainide, encainide, or moricizine)
C
Comparator
Placebo
O
Outcome
Mortalityhard clinical
The review emphasizes that specific treatment of asymptomatic ventricular premature beats with antiarrhythmic agents after myocardial infarction increases mortality and should be avoided.
Cite This Study
Andrew Tonkin (1992) studied this question.